Which companies are Tibet Duo Rui Pharmaceutical's closest peers?

The cockpit's peer set: Realcan Pharmaceutical (002589.SZ), Zhejiang Shouxiangu Pharmaceutical (603896.SS), Suzhou Ribo Life Science (6938.HK), Vigonvita Life Sciences (2630.HK), Neuren Pharmaceuticals (NEU.AX).

Is Tibet Duo Rui Pharmaceutical expensive compared with its peers?

On ev / sales it trades at 21.8× against a peer median of 34.1×, 3rd cheapest of 6 in its peer set.

How has Tibet Duo Rui Pharmaceutical stock performed?

Over six months to 6 Nov 2026 the shares returned -44.9% against -11.3% for the median peer; over one year -13.5%.

← CockpitCompetitor Analysis › 301075.SZ Tibet Duo Rui Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Tibet Duo Rui Pharmaceutical Co., Ltd. Class A301075.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Generic

Momentum laggard 9

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$552M

US dollars, full cap

$/day

$7.16M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-11.2 pp

WACC 9.3%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥46.00

1D-3.9%

1W+1.0%

1M-24.1%

3M-9.6%

6M-44.9%

YTD-22.9%

1Y-13.5%

ATR %7.2%

52w lowhigh53.2% off high

What Tibet Duo Rui Pharmaceutical does

Employees: 461

Tibet Duo Rui Pharmaceutical at a glance

Size Tibet Duo Rui Pharmaceutical (301075.SZ) is a China Health Care company (Pharmaceuticals: Generic) with a market value of $552M, the 3626th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥46.00 on 6 Nov 2026.

Performance Over six months the shares fell 44.9%, against -11.3% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 6 in its peer set.

Growth Revenue fell 6.2% over the last twelve months (peer median -3.9%); the operating margin is -34.0% (peer median -93.4%).

Valuation It trades at 21.8× enterprise value to sales against a peer median of 34.1× (3rd cheapest of 6).

Capital Return on invested capital runs 11.2 points below its cost of capital (9.3% WACC).

Relative performance

Six months, rebased to 100: Tibet Duo Rui Pharmaceutical against the median of its 5 peers (local-currency closes).

Tibet Duo Rui Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥166M	CN¥154M	CN¥240M	CN¥331M	CN¥397M
Revenue growth	—	-36%	-28%	-17%	—
Gross profit	CN¥51.9M	-CN¥7.54M	CN¥85.9M	CN¥215M	CN¥293M
EBITDA	n/a	-CN¥68.4M	-CN¥59.8M	CN¥18.5M	CN¥18.7M
Net income	-CN¥13.9M	-CN¥102M	-CN¥62.7M	CN¥18.9M	CN¥20.5M
Free cash flow	-CN¥206M	-CN¥144M	-CN¥105M	-CN¥8.47M	-CN¥30.2M
Capital expenditure	CN¥129M	CN¥102M	CN¥40.9M	CN¥23.7M	CN¥32.7M
Total debt	CN¥207M	CN¥439M	CN¥579M	CN¥205M	CN¥112M

Quarterly statements and history in the cockpit →

Tibet Duo Rui Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Tibet Duo Rui Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tibet Duo Rui Pharmaceutical is the large dot.

Tibet Duo Rui Pharmaceutical competitors and peer comparison

How Tibet Duo Rui Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tibet Duo Rui Pharmaceutical against its 5 peers (data as of 6 Nov 2026)
Measure	301075.SZ	Peer median	Rank in peer set
1-month return	-24.1%	-12.7%	lowest of 6
6-month return	-44.9%	-11.3%	lowest of 6
Distance from 52-week high	-53.2%	-40.3%	2nd lowest of 6
Revenue growth (TTM)	-6.2%	-3.9%	3rd lowest of 6
Operating margin	-34.0%	-93.4%	3rd highest of 5
EV / Sales	21.8×	34.1×	3rd cheapest of 6
ROIC minus cost of capital	-11.2 pp	-30.9 pp	3rd highest of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Tibet Duo Rui Pharmaceutical 301075.SZ	China	$552M	-45%	-6%	-34%	21.8×	n/a	n/a
Realcan Pharmaceutical 002589.SZ	China	$628M	-11%	-4%	0%	1.0×	17.7%	-23.1%
Zhejiang Shouxiangu Pharmaceutical 603896.SS	China	$398M	-22%	-10%	n/a	3.9×	n/a	n/a
Suzhou Ribo Life Science 6938.HK	Hong Kong	$939M	-29%	+4%	-187%	34.1×	n/a	n/a
Vigonvita Life Sciences 2630.HK	Hong Kong	$1.48B	-11%	+763%	-327%	109.3×	n/a	n/a
Neuren Pharmaceuticals NEU.AX	Australia	$2.04B	+83%	-68%	20%	38.3×	n/a	n/a

Questions

Which companies are Tibet Duo Rui Pharmaceutical's closest peers?: The cockpit's peer set: Realcan Pharmaceutical (002589.SZ), Zhejiang Shouxiangu Pharmaceutical (603896.SS), Suzhou Ribo Life Science (6938.HK), Vigonvita Life Sciences (2630.HK), Neuren Pharmaceuticals (NEU.AX).
Is Tibet Duo Rui Pharmaceutical expensive compared with its peers?: On ev / sales it trades at 21.8× against a peer median of 34.1×, 3rd cheapest of 6 in its peer set.
How has Tibet Duo Rui Pharmaceutical stock performed?: Over six months to 6 Nov 2026 the shares returned -44.9% against -11.3% for the median peer; over one year -13.5%.